Scotiabank initiated coverage of Pfizer (PFE) with an Outperform rating and $30 price target
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PFE:
- Novo Nordisk (NVO) Is Preparing to Launch Its New Weight Loss Pill – Here’s the Data
- Pharma firms spending billions on treatments based off old drugs, Bloomberg says
- FDA appoints Richard Pazdur as Director of CDER
- Pfizer call volume above normal and directionally bullish
- Cautious Optimism: Pfizer’s Strategic Initiatives and Clinical Trials Amidst Oncology Competition